Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Diffuse large b-cell lymphoma? 138 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 138 reports of Diffuse large b-cell lymphoma have been filed in association with INFLIXIMAB (Renflexis). This represents 0.1% of all adverse event reports for INFLIXIMAB.

138
Reports of Diffuse large b-cell lymphoma with INFLIXIMAB
0.1%
of all INFLIXIMAB reports
11
Deaths
58
Hospitalizations

How Dangerous Is Diffuse large b-cell lymphoma From INFLIXIMAB?

Of the 138 reports, 11 (8.0%) resulted in death, 58 (42.0%) required hospitalization, and 18 (13.0%) were considered life-threatening.

Is Diffuse large b-cell lymphoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 138 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Diffuse large b-cell lymphoma?

RITUXIMAB (1,571) CYCLOPHOSPHAMIDE (1,183) PREDNISONE (1,062) METHOTREXATE (1,055) VINCRISTINE (1,043) DOXORUBICIN (1,002) LENALIDOMIDE (779) TACROLIMUS (595) DEXAMETHASONE (539) PREDNISOLONE (506)

Which INFLIXIMAB Alternatives Have Lower Diffuse large b-cell lymphoma Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Diffuse large b-cell lymphoma Reports All Drugs Causing Diffuse large b-cell lymphoma INFLIXIMAB Demographics